Number of patients starting infliximab (from 1 March 2015 to 30 September 2016) or etanercept (from 1 April 2016 to 30 September 2016) originator or biosimilar, by line of treatment
| Infliximab | Etanercept | |||
|---|---|---|---|---|
| Originator | Biosimilars | Originator | Biosimilar | |
| Total | 570 | 1263 | 186 | 1607 |
| Bio- naïve | 379 (66%) | 508 (40%) | 89 (48%) | 581 (36%) |
| Non-medical switchers | – | 524 (42%) | – | 710 (44%) |
| Switchers from other biologics | 191 (34%) | 231 (18%) | 97 (52%) | 316 (20%) |